All In Biotech

Drug Trial Radar · NCT03749317

Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Viral Conjunctivitis

A Double-Masked, Placebo-Controlled, Randomized, Phase II Clinical Trial To Assess The Efficacy Of IVIEW-1201 In The Treatment Of Acute Adenoviral Conjunctivitis

Last checked: Nov 20, 2026Latest source record: Oct 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 135 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

135

Actual

Start

Feb 20, 2023

Primary completion

Apr 30, 2024

Study completion Dec 31, 2024

Sponsor

Lead sponsor
IVIEW Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Nov 21, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 15 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of IVIEW-1201 (1.0% Povidone-Iodine) Gel Forming Ophthalmic Solution Compared to Placebo in the Treatment of Adenoviral Conjunctivitis

Conditions

  • Adenoviral Conjunctivitis

Interventions

  • IVIEW-1201Drug

    IVIEW-1201; QID; one drop per eye, four times per day (QID) for 7 days

  • PlaceboDrug

    Placebo drug; QID; one drop per eye, four times per day (QID) for 7 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical resolution by assessment of bulbar conjunctival injection and watery conjunctival dischargeTime frame: Day 6 +/- 1 Day

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Disha Eye Hospital

    Kolkata, West Bengal, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.